Your browser doesn't support javascript.
loading
Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects.
Peixoto, Ana; Pinto, Pedro; Guerra, Joana; Pinheiro, Manuela; Santos, Catarina; Pinto, Carla; Santos, Rui; Escudeiro, Carla; Bartosch, Carla; Canário, Rita; Barbosa, Ana; Gouveia, Alfredo; Petiz, Almerinda; Abreu, Miguel Henriques; Sousa, Susana; Pereira, Deolinda; Silva, João; Teixeira, Manuel R.
  • Peixoto A; Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Pinto P; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Guerra J; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Pinheiro M; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Santos C; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Pinto C; Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Santos R; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Escudeiro C; Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Bartosch C; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Canário R; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Barbosa A; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Gouveia A; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Petiz A; Cancer Biology and Epigenetics Group, CI-IPOP, IPO Porto, Porto, Portugal.
  • Abreu MH; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Sousa S; Cancer Biology and Epigenetics Group, CI-IPOP, IPO Porto, Porto, Portugal.
  • Pereira D; Epithelial Interactions in Cancer Lab, Instituto de Investigação e Inovação em Saúde (I3S)/Instituto de Patologia e Imunologia Molecular da Universidade Do Porto (IPATIMUP), University of Porto, Porto, Portugal.
  • Silva J; Graduate Program in Areas of Basic and Applied Biology, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
  • Teixeira MR; Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Front Oncol ; 10: 1318, 2020.
Article en En | MEDLINE | ID: mdl-32850417
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2020 Tipo del documento: Article